読み込み中
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
前日終値
$1.395
+$0.025 · +1.82%
時間外
$1.43
+$0.035 · +2.51%
10月9日 19:58 ET
日中の時刻はETです。市場データは遅延する場合があります。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日中レンジ
現在 $1.395
52週レンジ
現在 $1.395
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
44
まちまち
リスク
73
高リスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日中レンジ
現在 $1.395
52週レンジ
現在 $1.395
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 448.58万 USD | −1069.72万 USD | 8802.6万 USD |
| 売上原価 | — | — | — | — | 4643.2万 USD |
| 粗利益 | — | — | 448.58万 USD | −1069.72万 USD | 4159.4万 USD |
| 研究開発 | 899.29万 USD | 1.59億 USD | 1.14億 USD | 1.56億 USD | 1.9億 USD |
| 販売・一般管理 | 448.38万 USD | 2.16億 USD | 6390.78万 USD | 2億 USD | 9億 USD |
| 営業費用 | 1347.67万 USD | 3.75億 USD | 5.16億 USD | 3.55億 USD | 21.13億 USD |
| 受取利息 | 108.81万 USD | 5464万 USD | 730.03万 USD | 495.4万 USD | 2133.3万 USD |
| 支払利息 | — | — | 10.19万 USD | — | — |
| 減価償却費と償却費 | 85.6万 USD | 710.76万 USD | 768.46万 USD | 948.1万 USD | 3162.99万 USD |
| 営業利益 | −1347.67万 USD | −3.75億 USD | −5.11億 USD | −3.66億 USD | −20.71億 USD |
| 純利益 | −661.46万 USD | −1.62億 USD | −14.66億 USD | −9.68億 USD | −23.32億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.25
上昇余地（491.40%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB88.91万0.01%102.79億 USD0.44%$206.49+3.00%
State Street SPDR Portfolio Emerging Markets ETFSPEM41.33万0.00%175.23億 USD0.07%$52.21+1.32%
ALPS Medical Breakthroughs ETFSBIO20.07万0.10%1.87億 USD0.50%$55.04+2.03%
State Street SPDR S&P China ETFGXC2.07万0.00%4.46億 USD0.59%$86.47+1.87%
ProShares Ultra Nasdaq BiotechnologyBIB6015.240.01%9320.36万 USD1.19%$110.98+5.68%iShares Biotechnology ETFIBBState Street SPDR Portfolio Emerging Markets ETFSPEMALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P China ETFGXCProShares Ultra Nasdaq BiotechnologyBIBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
